Based on the provided data for antiarrhythmic medicine sales in Canada, the values remain steady at 0.4 USD PPP per capita from 2024 to 2027 and then decline to 0.3 USD PPP per capita in 2028. Thus, no year-on-year variation is observed from 2024 to 2027. However, from 2027 to 2028, there is a 25% decrease in sales value. The Compound Annual Growth Rate (CAGR) over the five-year period is -5.59%.
Future trends to watch: Potential advancements in alternative treatments for arrhythmias, pharmaceutical innovations, and changes in healthcare policies and patient demographics could significantly impact the sales trajectory of antiarrhythmic medicines in Canada.
